As more products reach the market, therapy developers partner with researchers and regulators to deliver N-of-1 treatments to patients.
Aicuris’s pritelivir is forecast to be a significant advancement for immunocompromised patients with refractory HSV infections.
A 13-year-old boy with no history presented after 4 days of progressively worsening whole body rash.Nine days before ...
Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with ...
Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin ...
Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the ...
SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...
Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.
The biggest stories of the day delivered to your inbox.
Neuroinflammation and neuroimmune dysfunction are increasingly recognized as key contributors to AD pathophysiology, particularly in early disease stages. Semaglutide, already approved for type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results